FPTW
AZN icon

Franklin, Parlapiano, Turner & Welch’s AstraZeneca AZN Stock Holding History

Franklin, Parlapiano, Turner & Welch’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-50
Closed -$3K – 130
2016
Q3 		$3K Buy
+50
New +$3.27K ﹤0.01% 122

Other funds holding AZN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
EIP
Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return
BIM
BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Franklin, Parlapiano, Turner & Welch's AZN Position: Q4 2016 in Review

Franklin, Parlapiano, Turner & Welch sold out of AstraZeneca (AZN) in Q4 2016, closing a stake of 50 shares — an estimated $3K sold.

Franklin, Parlapiano, Turner & Welch first reported a position in AZN in Q3 2016 and held it in 1 quarter. The position peaked at $3K in Q3 2016. 450 funds tracked by Wall St. Rank hold AZN as of Q4 2016.

  • Franklin, Parlapiano, Turner & Welch reported no remaining AstraZeneca position as of Q4 2016 after selling out during the quarter.
  • Franklin, Parlapiano, Turner & Welch sold 50 AstraZeneca shares in Q4 2016, an estimated $3K.
  • Franklin, Parlapiano, Turner & Welch first reported a position in AstraZeneca in Q3 2016 and held it in 1 quarter.
  • Franklin, Parlapiano, Turner & Welch's AstraZeneca position peaked at $3K in Q3 2016.
  • 450 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2016.

Based on Franklin, Parlapiano, Turner & Welch's 13F filing for Q4 2016, filed 31 May 2017.